IMMUNE Pharmaceuticals has prioritized the development of Ferritin targeted combo Gemcitabine Paclitaxel NanomAbs. Total ferritin increased and shifted towards acidic (H-rich) ferritin in in the serum of patients with various malignancies such as colon cancer, testicular seminoma, breast cancer, squamous cell carcinoma of the head and neck. In research anti-Ferritin NanomAbs showed marked affinity and improved efficacy for specific tumors such as pancreas and NSCLC. The combination of two drugs induces synergistic anti-tumor effect, while the targeted delivery specifically to tumor cell reduces undesired effects.
NanomAbs comprise four basic modules:
PEGylated polymeric nanoparticles (PPNs) act as a scaffold which shields the drug from premature elimination or off-target effects.
Proprietary linker molecules embedded within the PPN connect the mAb to the rest of the particle.
Anti-cancer drug (incorporated within the PEGylated polymeric nanoparticles). Several chemotherapeutic drugs with different mechanism of action have been successfully incorporated as lipophilic prodrugs within NanomAbs, e.g. Paclitaxel, Gemcitabine and Oxaliplatin.
- Therapeutic mAb mainly functions as a targeting ligand by binding to a specific tumor antigen. Several mAbs have been tested and are being used in NanomAbs products currently developed, including HER2, HER3, EGFR and Ferritin targeting mAbs.